Tahir Amin

China’s State Intellectual Property Office (SIPO) has decided to reject a Gilead Sciences, Inc. (NASDAQ: GILD)’s patent application relating to its hepatitis C (HCV) drug sofosbuvir, marketed as Sovaldi. The rejection could have important implications for Gilead, its generic drug...